Live Vaccines and Cosentyx Timing
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune responses. Avoid live vaccines during treatment and for up to 9 months after stopping, as they risk disseminated infection. Use only non-live vaccines, like inactivated flu or COVID-19 shots.[1][2]
Recommended Vaccination Approach
Vaccinate patients before starting Cosentyx when possible, especially for routine shots like pneumococcal, influenza, shingles (Shingrix, recombinant), hepatitis B, HPV, and tetanus. Post-treatment, monitor antibody responses—they may be reduced, requiring boosters or titer checks for high-risk patients (e.g., elderly or immunocompromised).[1][3]
Active Infections and Screening
Delay vaccination if patients have acute infections. Screen for tuberculosis (TB) and hepatitis B before initiating Cosentyx, as it increases reactivation risk. Positive tests may need treatment first.[1][2]
Specific Vaccine Considerations
- Shingles (Zoster): Prefer recombinant Shingrix over live Zostavax; administer 2-4 weeks pre-Cosentyx.
- COVID-19: Safe with mRNA or protein-based vaccines; no specific timing issues beyond general IL-17 rules.
- Pneumococcal: PCV13 or PPSV23 recommended pre-treatment for at-risk groups.[3][4]
| Vaccine Type | Timing Relative to Cosentyx | Notes |
|--------------|-----------------------------|-------|
| Live (e.g., MMR, varicella, oral polio) | Avoid during + 9 months after | Risk of severe infection |
| Inactivated/Non-live (e.g., flu, Tdap, HPV) | Anytime, prefer pre-treatment | May have lower efficacy |
| Recombinant subunit (e.g., Shingrix) | 2-4 weeks before start | Stronger immune response pre-therapy |
Patient Risk Factors
Higher caution for those with chronic infections, recent live vaccine exposure, or on combo immunosuppressants (e.g., methotrexate). Pediatric patients (under 6 for some indications) need extra scrutiny for routine immunization catch-up.[1][5]
Monitoring and Follow-Up
Post-vaccination, test immunogenicity if infection risk is high (e.g., anti-HBV titers). Report any unusual vaccine reactions to VAERS. Consult infectious disease specialists for complex cases.[2][4]
Sources
[1] Cosentyx Prescribing Information (Novartis)
[2] CDC Guidelines: Vaccinations in Immunocompromised Patients
[3] ACR Guidelines: Vaccinations in Rheumatic Diseases
[4] IDSA Recommendations for Biologic Users
[5] FDA Label for Secukinumab